Clopidogrel Bisulfate Tablet, Film Coated
Product Images NDC 77771-124

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Clopidogrel Bisulfate (NDC 77771-124). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Radha Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

75 mg Label 1000 (Clopidogrel 75mg 1000tablets)

This is a description of a medication called Clopidogrel bisulfate. Each tablet contains 97.875 mg of Clopidogrel bisulfate, which is equivalent to 75 mg of clopidogrel. The recommended dosage for adults should be followed, as described in the accompanying prescribing information. The tablets should be stored at room temperature (25°C or 77°F), with excursions permitted between 15°to 30°C (59° to 86°F). The medication is distributed by Radha Pharmaceuticals and manufactured by ScieGen Pharmaceuticals. This medication requires a prescription to dispense, and the medication guide should be provided separately to each patient.*

FDA Label Image

75 mg Label 30 (Clopidogrel 75mg 30tablets)

This is a description of a medication named "Clopidogrel bisulfate, USP" contained in tablets. The tablets come in a bottle of 30 and are manufactured by ScieGen Pharmaceuticals, Inc. It includes directions on storage and prescribing information for adults. The medication guide must be dispensed to each patient by the pharmacist. The medication is distributed by Radha Pharmaceuticals, Inc. in Hauppauge, NY, USA.*

FDA Label Image

75 mg Label 90 (Clopidogrel 75mg 90tablets)

Each tablet contains Clopidogre bisulfate, USP. It is a medication used to prevent blood clots in people who have had a recent heart attack, stroke or circulation problem. The usual adult dosage is recommended to be T-Tablets, USP. It should be stored at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F). Compliance with USP Controlled Room Temperature is recommended. The manufacturer recommends dispensing the accompanying medication guide to each patient.*

FDA Label Image

Figure1 (Clopidogrel Fig 1)

This text appears to be a chart or table displaying the effect of different proton pump inhibitors (PPIs) at varying dosages on the active metabolite AUC. The PPIs listed are dexlansoprazole, lansoprazole, pantoprazole, and omeprazole, with dosages ranging from 30-80 mg. The chart also shows mean and 90% confidence interval data for the AUC. There is a reference to "change relative to clopidogrel administered alone," indicating that this may be a study looking at the impact of PPIs on the efficacy of the drug clopidogrel.*

FDA Label Image

Figure3 (Clopidogrel Fig 2)

The given text represents a table showing the cumulative event rate (in percentages) for cardiovascular death, myocardial infarction, and stroke for patients receiving placebo with aspirin and clopidogrel with aspirin. The table also shows the months of follow-up.*

FDA Label Image

Figure3 (Clopidogrel Fig 3)

FDA Label Image

Figure4 (Clopidogrel Fig 4)

The text appears to be a summary of data related to the usage of Clopidogrel medication, suggesting a 7% proportional risk reduction in deaths compared to the control group, with a p-value of 0.03. The other numbers may refer to the number of days since randomization and some percentage figures.*

FDA Label Image

Figure5 (Clopidogrel Fig 5)

The text describes the results of a study comparing the effectiveness of Placebo and Clopidogrel in reducing re-infarction and preventing stroke, based on the number and percentage of events observed in each group. It also presents a graph showing the number of events over time since randomization, with the results up to 28 days being shown.*

FDA Label Image

Figure6 (Clopidogrel Fig 6)

This text seems to be a table with multiple headers and axis titles, likely extracted from a research study. It includes various subgroup characteristics including gender, age-group, hours since onset, medication given, etc. Additionally, it features percentages of a drug called Clopidogrel versus a placebo drug. However, as the table values appear to be heavily corrupted during , it is not possible to determine the results of the study.*

FDA Label Image

Figure7 (Clopidogrel Fig 7)

This is a chart that displays the cumulative event rate (percentage) of fatal or non-fatal vascular events over a period of 30 months of follow-up. The chart compares the use of aspirin and clopidogrel.*

FDA Label Image

Figure8 (Clopidogrel Fig 8)

FDA Label Image

Structure (Clopidogrel Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.